<div id="readability-page-1"><p>Doximity, Inc. (NYSE:DOCS - Get Free Report)'s share price hit a new 52-week low on Thursday after an insider sold shares in the company. The company traded as low as $17.32 and last traded at $17.8060, with a volume of 3490995 shares traded. The stock had previously closed at $23.39.</p><ul><li>Doximity is the Facebook and LinkedIn of the Medical Community</li></ul><p>Specifically,  insider Siddharth Sitaram sold 2,309 shares of the firm's stock in a transaction on Monday, May 11th. The stock was sold at an average price of $25.77, for a total transaction of $59,502.93. Following the completion of the transaction, the insider directly owned 89,396 shares in the company, valued at $2,303,734.92. This trade represents a 2.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kira Scherer Wampler sold 9,000 shares of the firm's stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $26.06, for a total transaction of $234,540.00. Following the sale, the director owned 19,839 shares of the company's stock, valued at approximately $517,004.34. This represents a 31.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. </p><h2>Wall Street Analyst Weigh In</h2><p>A number of analysts have commented on the company. Canaccord Genuity Group  set a $34.00 target price on Doximity and gave the stock a &#34;buy&#34; rating in a report on Monday, February 9th. Morgan Stanley reduced their price objective on Doximity from $49.00 to $35.00 and set an &#34;overweight&#34; rating for the company in a report on Thursday. KeyCorp cut shares of Doximity from an &#34;overweight&#34; rating to a &#34;sector weight&#34; rating in a research note on Thursday. BMO Capital Markets reduced their price target on shares of Doximity from $25.00 to $20.00 and set a &#34;market perform&#34; rating for the company in a research note on Thursday. Finally, Robert W. Baird  restated a &#34;neutral&#34; rating and set a $18.00 price objective (down from $40.00) on shares of Doximity in a research report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and thirteen have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock  has an average rating of &#34;Moderate Buy&#34; and an average price target of $32.38.</p><ul><li>Doximity is an Overlooked Medical Ecosystem AI Play </li></ul><p><b>View Our Latest Stock Analysis on DOCS</b></p><h2>More Doximity News</h2><p>Here are the key news stories impacting Doximity this week:</p><ul>   <li><span>Positive Sentiment: </span>Doximity reported adjusted EPS of $0.26, topping one analyst estimate, and revenue rose 5.1% year over year to $145.37 million, showing the business is still growing. <i></i><span>Doximity Earnings Report</span></li>   <li><span>Positive Sentiment: </span>The company highlighted strong profitability, including a 37.54% net margin and 23.84% return on equity, which supports its high-margin business model. <i></i><span>Fiscal Q4 Earnings Snapshot</span></li>   <li><span>Neutral Sentiment: </span>Insider Siddharth Sitaram sold 2,309 shares, but the transaction was part of a pre-arranged 10b5-1 plan and tied to tax withholding from equity vesting, making it less concerning than a discretionary sale. <i></i><span>Insider Sale Disclosure</span></li>   <li><span>Negative Sentiment: </span>Investors focused on the fact that Doximity missed broader earnings expectations, with EPS of $0.26 versus the Zacks consensus of $0.28, which suggests the quarter was not as strong as headline results implied. <i></i><span>Doximity Lags Q4 Earnings Estimates</span></li>   <li><span>Negative Sentiment: </span>More importantly, management’s FY2027 and Q1 FY2027 revenue guidance came in below Wall Street estimates, fueling concerns about slowing growth and higher spending related to AI investments. <i></i><span>Doximity Q4 2026 Earnings Call Transcript</span></li>   <li><span>Negative Sentiment: </span>Brokerage firms also turned more cautious, with BMO Capital Markets cutting its price target to $20 and Mizuho lowering its target to $26, reinforcing the weaker sentiment around the stock. <i></i><span>Analyst Price Target Changes</span></li> </ul><h2>Doximity Price Performance</h2><ul><li>Doximity Stock is an Interesting Healthcare Play</li></ul><p>The company has a market capitalization of $3.28 billion, a P/E ratio of 14.84, a P/E/G ratio of 1.88 and a beta of 1.36. The stock has a fifty day simple moving average of $24.27. </p><p>Doximity declared that its board has approved a stock repurchase program on Thursday, February 5th that authorizes the company to repurchase $500.00 million in  outstanding  shares. This repurchase authorization authorizes the company to buy up to 8% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company's leadership believes its shares are undervalued. </p><h2>Institutional Inflows and Outflows</h2><p>A number of large investors have recently made changes to their positions in DOCS. Royal Bank of Canada lifted its holdings in  Doximity by 24.2% in the 1st quarter. Royal Bank of Canada now owns 106,845 shares of the company's stock worth $6,200,000 after purchasing an additional 20,847 shares in the last quarter.  MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of  Doximity by 0.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,978 shares of the company's stock valued at $2,262,000 after buying an additional 210 shares during the last quarter.  NewEdge Advisors LLC lifted its holdings in shares of  Doximity by 613.7% in the first quarter. NewEdge Advisors LLC now owns 6,323 shares of the company's stock worth $367,000 after buying an additional 5,437 shares in the last quarter.  Goldman Sachs Group Inc. lifted its holdings in shares of  Doximity by 33.3% in the first quarter. Goldman Sachs Group Inc. now owns 255,529 shares of the company's stock worth $14,828,000 after buying an additional 63,873 shares in the last quarter.  Finally, Focus Partners Wealth bought a new position in shares of  Doximity during the first quarter worth $283,000. 87.19% of the stock is owned by hedge funds and other institutional investors. </p><h2>Doximity Company Profile</h2> (Get Free Report)<p>Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers. </p><p>The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Doximity</li><li>eVTOL Investing: Ditch the Taxi, Buy the Blueprint</li><li>How Berkshire’s New York Times Bet Looks Today</li><li>Affirm's Google Deal Aims for Your Wallet</li><li>Airplane Maintenance Companies That Keep Flights Moving Are Ready to Soar</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Doximity Right Now?</h2><p>Before you consider Doximity, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.</p><p>While Doximity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

DOCS

LGHT

HEAL

<p>Doximity (NYSE:DOCS) reached a new 52-week low of $17.32 following insider selling, with shares last trading at $17.8060. Insider Siddharth Sitaram sold 2,309 shares at $25.77, while Director Kira Scherer Wampler sold 9,000 shares at $26.06. Analysts have mixed views, with price targets ranging from $18.00 to $34.00. Despite reporting a 5.1% revenue increase, the company missed earnings expectations and provided lower revenue guidance for FY2027, raising concerns about growth. Doximity's board approved a $500 million stock repurchase program, indicating confidence in the stock's value.</p>

Market Beat

Doximity

Langar Global HealthTech ETF

Global X HealthTech ETF

First Trust Nasdaq Lux Digital Health Solutions ETF

Morgan Stanley

KeyCorp

Bank of Montreal

Mizuho Financial

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

Mizuho Financial Group, Inc.

Doximity (NYSE:DOCS) Sets New 52-Week Low After Insider Selling